First Eagle Investment Management LLC Has $20.08 Million Stock Position in Haleon plc (NYSE:HLN)

First Eagle Investment Management LLC lifted its stake in Haleon plc (NYSE:HLN) by 4.7% during the 4th quarter, HoldingsChannel reports. The fund owned 2,104,289 shares of the company’s stock after buying an additional 93,553 shares during the period. First Eagle Investment Management LLC’s holdings in Haleon were worth $20,075,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. FMR LLC boosted its stake in Haleon by 5.8% during the third quarter. FMR LLC now owns 104,918,269 shares of the company’s stock worth $1,110,035,000 after buying an additional 5,768,117 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Haleon during the fourth quarter worth $42,193,000. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Haleon during the fourth quarter worth $39,628,000. Wellington Management Group LLP boosted its stake in Haleon by 49.9% during the third quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock worth $96,833,000 after buying an additional 3,046,841 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Haleon by 25.3% during the third quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock worth $53,791,000 after buying an additional 1,026,939 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Stock Performance

Haleon stock opened at $10.19 on Friday. The stock has a 50-day simple moving average of $9.72 and a 200 day simple moving average of $9.87. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80. The stock has a market capitalization of $46.11 billion, a price-to-earnings ratio of 29.96, a P/E/G ratio of 2.82 and a beta of 0.25.

Haleon (NYSE:HLN) last released its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The business had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.38 billion. On average, research analysts anticipate that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The firm also recently declared a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be issued a $0.1166 dividend. This represents a dividend yield of 1.6%. This is a boost from Haleon’s previous — dividend of $0.05. The ex-dividend date of this dividend is Friday, April 25th. Haleon’s payout ratio is currently 58.97%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on HLN shares. Morgan Stanley cut Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Haleon in a report on Monday, March 3rd. HSBC reissued a “hold” rating on shares of Haleon in a report on Wednesday, March 5th. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Finally, Hsbc Global Res cut Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Six analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.